Controlling refractory atonic postpartum hemorrhage with Hemabate sterile solution

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Reproductive Medicine

Background:

• Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality worldwide.
• Effective pharmacologic interventions are crucial for managing PPH and preventing severe complications.
• Hemabate sterile solution (carboprost tromethamine) is a recognized treatment option for PPH.

Purpose of the Study:

• To evaluate the efficacy and outcomes of using Hemabate sterile solution for treating postpartum hemorrhage.
• To identify patient characteristics and conditions associated with the use and success of Hemabate.
• To assess the overall success rate and factors contributing to treatment failure.

Main Methods:

• A prospective study conducted over 12 months across 12 obstetrics units.
• Involved the administration of Hemabate sterile solution to patients with postpartum hemorrhage.
• Outcomes assessed included patient characteristics, drug administration conditions, and post-treatment status, with bleeding cessation as the primary success criterion.

Main Results:

• Hemabate sterile solution successfully controlled bleeding in 208 out of 237 cases (87.8%) immediately after administration.
• An overall success rate of 94.9% was achieved when considering additional administrations of oxytocics.
• Twelve cases (5.1%) were considered pharmacologic treatment failures, necessitating surgical intervention.

Conclusions:

• Hemabate sterile solution demonstrates high efficacy in controlling postpartum hemorrhage.
• While several factors (e.g., coagulopathy, retained products, lacerations) were noted in treatment failures, no single combination was consistently predictive.
• The study supports the use of Hemabate as a key pharmacologic agent in the management of PPH.